Eylea HD
Eylea HD (aflibercept 8 mg) — Regeneron A high-dose VEGF inhibitor jointly developed by Regeneron and Bayer, used to treat
wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. FDA approved in August 2023.
Social media
"Partnership in Motion" (LinkedIn/Meta)
A single continuous line ties the visual system together, reinforcing Regeneron's
message of partnership and support for EYLEA HD providers and patients.
ASRS 2025 Pre-Congress LinkedIn Ad (3 cards)
A pre-congress LinkedIn carousel building awareness ahead of ASRS 2025 in Long Beach,
using real-world patient imagery to anchor the "Discover Real Data. Patients. Impact." theme
and drive booth traffic.
Brand guidelines
Clinical practice case
Journal spread ad
Cover tip
Cover tip - J-code update
"September is Healthy Aging Month" (LinkedIn/Meta)
A visual metaphor for clearing vision. Reinforcing that Wet AMD is a
leading cause of vision loss in older adults, and the need for early screening.
ASRS 2025 In-Congress LinkedIn Ad (4 cards)
A pre-congress LinkedIn carousel building awareness ahead of ASRS 2025 in Long Beach,
using real-world patient imagery to anchor the "Discover Real Data. Patients. Impact." theme
and drive booth traffic.
